Radisys Announces Availability of Industry-first Release 17 Compliant 5G NR Solution
22.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced its Release 17 compliant 5G NR software solution, extending its award-winning Release 16 Software with advanced features like non-terrestrial networks (NTN) and integrated access and backhaul (IAB) that expands coverage ability for 5G Networks. Release 17 relay node and satellite access capabilities will improve worldwide cellular service availability by enhancing the accessibility of fast and reliable 5G connectivity for unserved and underserved areas. In addition to driving ubiquitous 5G consumer access, Radisys’ Release 17 compliant 5G NR software supports enterprise, infrastructure and public safety use cases including intelligent transportation systems (ITS), aeronautic broadband, maritime, critical communications, fleet management, smart factories, and Internet of Things (IoT) devices.
Radisys’ Connect RAN 5G solution facilitates a flexible 5G network to meet varied deployment requirements and provide universal 5G connectivity for diverse applications and use cases. By deploying Connect RAN 5G software, customers can minimize their development costs and operational and capital expenses while at the same time improving time-to-market and shortening their return on investment.
News Highlights
- Radisys’ Release 17 compliant RAN software continues its proven track record of 5G R&D innovation, enabling 5G Network connectivity for diverse service enabler ultra-reliable low latency communication (URLLC), and eMBB use cases across a wide set of FR1and FR2 bands for multiple deployment and access options.
- Radisys’ Connect RAN 5G software’s NTN feature supports geostationary, medium and low earth orbit (GEO/MEO/LEO) satellite access with flexible and scalable software architecture and well-defined interfaces to SATCOM infrastructure. Radisys’ NTN software empowers OEMs and ODMs to unlock newer business opportunities by leveraging the significant investment being made in SATCOM technology.
- Radisys’ IAB feature enhances centralized (CU) and distributed (DU) units to service relay nodes as 3GPP compliant Donor CUs and Donor DUs. It also includes IAB/Relay node comprising IAB-DU and IAB-MT software that provides end-to-end IAB solution integration with industry-leading platforms.
- Radisys’ Release 17 compliant RAN software provides a foundation for features such as NR positioning, reduced capability (RedCap), and NR SideLink enabling OEMs, ODMs and operators to cost-effectively scale their 5G networks.
“We are excited to launch the first-to-market Release 17 Connect RAN 5G Software delivering expanded 5G connectivity and service accessibility, enabling our customers to unlock newer business opportunities,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “With advanced features like NTN and IAB, Radisys continues to be a leader in delivering ORAN-compliant multi-architecture and multi-platform 5G software to our customers, driving business use cases across a variety of industry verticals.”
Meet with Radisys at MWC Barcelona
See demonstrations of Radisys’ industry-first Release 17 compliant 5G NR Solution, at MWC Barcelona, Stand 5B81. To schedule a meeting with Radisys’ mobility experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005290/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom